SAN DIEGO, September 29, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of

SAN DIEGO, Aug. 25, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory

-Prometheus to receive an upfront payment and payments upon achievement of several milestones expected within the next 12 months– -Falk to pay 25% of global development costs of IBD program- -Falk to leverage the Prometheus 360™ platform to create next-generation IBD precision medicines- SAN DIEGO

SAN DIEGO, August 4, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory

Agreement Leverages Prometheus Biosciences’ Proprietary Bioinformatics Analysis Platform, Companion Diagnostics to Speed Development and Discovery SAN DIEGO, Oct. 3, 2019 / PRNewswire / —  Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and

Company Plans to Complete Series C Financing in Fourth Quarter of 2019, Followed by Initial Public Offering for 2020   SAN DIEGO, Sept. 5, 2019 /PRNewswire/ — Precision IBD, Inc., a biopharmaceutical company focused on the discovery and development of a broad portfolio of precision therapeutics and